Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MSH6 negative Pembrolizumab ovary epithelial cancer sensitive detail...
MLH1 negative Pembrolizumab ovary epithelial cancer sensitive detail...
MSH6 negative Dostarlimab-gxly ovary epithelial cancer sensitive detail...
MLH1 negative Dostarlimab-gxly ovary epithelial cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib ovary epithelial cancer sensitive detail...
RET fusion Selpercatinib ovary epithelial cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00703105 Phase II Denileukin diftitox Ovarian Dendritic Cell Vaccine Trial Unknown status USA 0
NCT01012817 Phase Ib/II Topotecan + Veliparib Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT01145430 Phase I Pegylated liposomal doxorubicin + Veliparib Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Completed USA 0
NCT01146795 Phase II Bevacizumab + Carboplatin + Paclitaxel Neoadjuvant Therapy for Ovarian Cancer Completed USA 0
NCT01239732 Phase III Bevacizumab + Carboplatin + Paclitaxel A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NLD | ITA | FRA | ESP | CAN | AUT 31
NCT01482715 Phase Ib/II Rucaparib A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed USA | GBR | ESP | CAN 1
NCT01519869 Phase I Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Completed USA 0
NCT01535157 Phase Ib/II Ketoconazole Fenretinide Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Terminated USA 0
NCT01536743 Phase II Palbociclib A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression Completed USA 0
NCT01649336 Phase I Binimetinib + Paclitaxel A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Completed USA 0
NCT01690468 Phase Ib/II Carboplatin + Triciribine PTX-200 and Carboplatin in Ovarian Cancer Terminated USA 0
NCT01749397 Phase I Floxuridine + Veliparib Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed USA 0
NCT01846611 Phase III Pegylated liposomal doxorubicin Dexamethasone A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed USA | NZL | GBR | AUS 6
NCT01853644 Phase II Tivozanib Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed USA 0
NCT01891344 Phase II Rucaparib A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Completed USA | GBR | FRA | ESP | CAN | AUS 0
NCT01968213 Phase III Rucaparib A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 1
NCT01991210 Phase II DNIB0600A Pegylated liposomal doxorubicin A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer Terminated USA | GBR | FRA | ESP | CAN | BEL 1
NCT02033616 Phase II Ovapuldencel-T Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Unknown status USA 0
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Completed USA | CAN 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02188550 Phase II Everolimus + Letrozole Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status USA 0
NCT02195973 Phase Ib/II Paclitaxel + Sonidegib Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Completed USA 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02272790 Phase II Adavosertib + Pegylated liposomal doxorubicin Adavosertib + Carboplatin Adavosertib + Gemcitabine Adavosertib + Paclitaxel Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed USA | NLD | CAN 0
NCT02275039 Phase I MVAp53 Gemcitabine p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed USA 0
NCT02278783 Phase II Regorafenib Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer Terminated USA 0
NCT02289950 Phase II Farletuzumab A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer Completed USA | ITA | GBR | ESP | DEU | BEL 1
NCT02354131 Phase Ib/II Niraparib Bevacizumab + Niraparib Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA) Completed USA 1
NCT02364713 Phase II Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Active, not recruiting USA 0
NCT02392676 Phase III Olaparib Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations Withdrawn USA | GBR 3
NCT02534922 Phase I Prolanta Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC) Unknown status USA 0
NCT02537444 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) Completed USA 0
NCT02539719 Phase I Budigalimab + SC-003 SC-003 Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer Terminated USA 0
NCT02540356 Phase Ib/II Imalumab Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU 1
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) Completed USA 0
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | NZL | GBR | FRA | ESP | AUS 0
NCT02674061 Phase II Pembrolizumab Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) Completed 0
NCT02713386 Phase Ib/II Ruxolitinib Carboplatin + Paclitaxel Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT02718417 Phase III Avelumab Carboplatin + Paclitaxel Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) Terminated USA | NLD | ITA | GBR | DEU | CAN 19
NCT02726997 Phase Ib/II Carboplatin + Durvalumab + Paclitaxel Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer Active, not recruiting USA 0
NCT02728830 Phase I Pembrolizumab A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Completed USA 0
NCT02766582 Phase II Carboplatin + Paclitaxel + Pembrolizumab Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer Completed USA 0
NCT02785250 Phase I Cyclophosphamide + Epacadostat + Maveropepimut-S Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer Active, not recruiting USA | CAN 0
NCT02788708 Phase I Lenvatinib + Paclitaxel Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Completed USA 0
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Completed CAN 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02833506 Phase I NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn USA 0
NCT02834975 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). Terminated USA 0
NCT02853318 Phase II Bevacizumab + Cyclophosphamide + Pembrolizumab Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT02855944 Phase III Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed USA | ITA | GBR | ESP | CAN 7
NCT02865811 Phase II Pegylated liposomal doxorubicin + Pembrolizumab Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer Completed USA 0
NCT02873962 Phase II Bevacizumab + Nivolumab A Phase II Study Of Nivolumab/ Bevacizumab Active, not recruiting USA 0
NCT02884648 Phase II Bevacizumab Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery Recruiting USA 0
NCT02900560 Phase II Azacitidine + Pembrolizumab Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer Terminated USA 0
NCT02901899 Phase II Guadecitabine + Pembrolizumab Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed USA 0
NCT02915523 Phase Ib/II Avelumab Avelumab + Entinostat Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Completed USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting USA 0
NCT02923739 Phase II Bevacizumab + Emactuzumab + Paclitaxel Bevacizumab + Paclitaxel Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT Terminated USA 0
NCT02943317 Phase I Defactinib Avelumab Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Terminated USA 0
NCT02948101 Phase II Cyclophosphamide + PD 0360324 Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer Withdrawn USA 0
NCT02948426 Phase I Interferon gamma + Peginterferon alfa-2b Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Terminated USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03038100 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) Completed USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 14
NCT03054909 Phase I Nogapendekin alfa inbakicept QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer Completed USA 0
NCT03078400 Phase I SPL-108 Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Unknown status USA 0
NCT03079687 Expanded access Olaparib Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Approved for marketing USA 0
NCT03081702 Phase Ib/II Hydroxychloroquine + Itraconazole A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer Completed CAN 0
NCT03093155 Phase II Bevacizumab + Ixabepilone Ixabepilone Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Completed USA 0
NCT03106987 Phase III Olaparib A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO) Completed ITA | GBR | FRA | ESP | DEU | CAN | BEL 4
NCT03113487 Phase II MVAp53 + Pembrolizumab P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting USA 0
NCT03138408 Phase I SC-004 Budigalimab + SC-004 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers Terminated USA 0
NCT03162562 Phase I Oregovomab + Poly ICLC The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Terminated USA 0
NCT03206047 Phase Ib/II Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03206645 Phase I Carboplatin + Paclitaxel + PTC596 PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy Completed USA 0
NCT03213964 Phase I Aldesleukin + FATE-NK100 Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int Completed USA 0
NCT03245892 Phase I Carboplatin + Nivolumab + Paclitaxel A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer Active, not recruiting USA 0
NCT03246074 Phase I Fostamatinib + Paclitaxel Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer Active, not recruiting USA 0
NCT03287271 Phase Ib/II Defactinib ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK Recruiting USA 0
NCT03312114 Phase II Avelumab Anti—PD-L1 and SAbR for Ovarian Cancer Terminated USA 0
NCT03318900 Phase I Aldesleukin + Cyclophosphamide + Utomilumab T Cell Immunotherapy for Advanced Ovarian Cancer Completed USA 0
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Active, not recruiting USA 0
NCT03326193 Phase II Bevacizumab + Niraparib Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting USA 0
NCT03394885 Phase Ib/II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) Completed USA 0
NCT03398655 Phase III Paclitaxel Paclitaxel + VB-111 A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL) Completed USA | ESP 3
NCT03410784 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO28MaNGOov4) Recruiting ITA 0
NCT03430518 Phase I Durvalumab + Eribulin Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Completed USA 0
NCT03462212 Phase Ib/II Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) Recruiting ITA 0
NCT03519178 Phase II PF-06873600 A Study of PF-06873600 in People With Cancer Active, not recruiting USA | CAN 4
NCT03522246 Phase III Rucaparib Nivolumab Nivolumab + Rucaparib A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) Active, not recruiting USA | NZL | ITA | GBR | ESP | DEU | CAN | BEL | AUS 15
NCT03558139 Phase I Avelumab + Hu5F9-G4 A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer Completed USA 0
NCT03564340 Phase Ib/II Cemiplimab + REGN4018 REGN4018 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT03574779 Phase II Bevacizumab + Dostarlimab-gxly + Niraparib Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL) Recruiting USA | ESP | CAN 0
NCT03579316 Phase II Olaparib Adavosertib + Olaparib Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting USA 0
NCT03596281 Phase I Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) Active, not recruiting FRA 0
NCT03607955 Phase I AVB-S6-500 + Carboplatin + Paclitaxel Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy Withdrawn 0
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Terminated USA | NLD | ITA | ESP | CAN | BEL 2
NCT03642132 Phase III Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Talazoparib Avelumab + Carboplatin + Paclitaxel + Talazoparib Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Terminated USA | ITA | BEL | AUS 6
NCT03657043 Phase II Tisotumab vedotin-tftv A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) Completed USA | ITA | ESP | BEL 2
NCT03691376 Phase I Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT03704467 Phase II Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Avelumab + Berzosertib + Carboplatin Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer Completed USA | GBR | BEL 0
NCT03732950 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT03734692 Phase Ib/II Cisplatin + Pembrolizumab + Rintatolimod Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Recruiting USA 0
NCT03735589 Phase Ib/II alphaDC1 + NK-like CTLs Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn USA 0
NCT03740165 Phase III Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT03748186 Phase I Luveltamab Tazevibulin Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers Recruiting USA | ESP 0
NCT03756818 Phase I Mivavotinib + Paclitaxel TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Completed USA 0
NCT03824704 Phase II Nivolumab + Rucaparib A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Terminated USA 0
NCT03836352 Phase II Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting USA | CAN 0
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Terminated USA 0
NCT03872206 Phase Ib/II HPN536 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Completed USA 0
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03943173 Phase I Olaparib Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Active, not recruiting USA 0
NCT03959761 Phase Ib/II Nivolumab Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) Unknown status FRA 0
NCT04019288 Phase Ib/II AVB-S6-500 + Durvalumab AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT04024878 Phase I NeoVax + Nivolumab NeoVax With Nivolumab in Patients With Ovarian Cancer Active, not recruiting USA 0
NCT04055649 Phase II ONC201 + Paclitaxel ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting USA 0
NCT04092270 Phase I Pegylated liposomal doxorubicin + Peposertib A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients Recruiting USA 0
NCT04111978 Phase III Letrozole MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO) Recruiting DEU | AUT 1
NCT04122625 Phase Ib/II Nivolumab + Xevinapant Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Completed USA | FRA | ESP 0
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting USA 1
NCT04182516 Phase I NMS-03305293 Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Active, not recruiting USA | ITA | GBR 3
NCT04239014 Phase II Olaparib Ceralasertib + Olaparib A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE) Withdrawn USA | ITA | ESP | CAN 0
NCT04267939 Phase I Elimusertib + Niraparib ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Terminated USA 0
NCT04274426 Phase II Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA) Recruiting DEU 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA | GBR | FRA | ESP 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04469764 Phase II Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Recruiting USA 0
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Recruiting USA | NLD | ITA | GBR | ESP | CAN | BEL | AUS 9
NCT04493619 Phase Ib/II Carboplatin + PLX2853 PLX2853 PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Terminated USA | CAN 0
NCT04498520 Phase I Abexinostat + Fulvestrant + Palbociclib Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Withdrawn 0
NCT04516447 Phase I Pegylated liposomal doxorubicin + ZN-c3 Carboplatin + ZN-c3 A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer Recruiting USA | AUS 5
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Active, not recruiting USA 5
NCT04561817 Phase II Ipatasertib + Paclitaxel To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer Withdrawn USA 0
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Active, not recruiting USA 0
NCT04590326 Phase Ib/II REGN4018 + REGN5668 Cemiplimab + REGN5668 Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. Recruiting USA | BEL 0
NCT04598321 Phase I Talazoparib BrUOG 390: Neoadjuvant Treatment With Talazoparib Terminated USA 0
NCT04630769 Phase I Aldesleukin + FT516 Aldesleukin + FT516 + MGA271 FT516 and IL2 With Enoblituzumab for Ovarian Cancer Completed USA 0
NCT04633239 Phase I Abemaciclib + Olaparib Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer Recruiting USA 0
NCT04676334 Phase III Rucaparib CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) Completed ITA | GBR | CAN 3
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04713514 Phase II OSE 2101 + Pembrolizumab OSE 2101 OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA) Recruiting FRA | DEU | BEL 0
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Terminated USA 0
NCT04753216 Phase II Bevacizumab + Liposomal irinotecan Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT04781088 Phase II Lenvatinib + Paclitaxel + Pembrolizumab Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT04787289 Phase II Bevacizumab A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer Recruiting CAN 0
NCT04809805 Phase I BAY2666605 A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer Terminated USA 0
NCT04840589 Phase I Ipilimumab + Nivolumab + ZEN-3694 Nivolumab + ZEN-3694 Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors Recruiting USA 0
NCT04887961 Phase II Pegylated liposomal doxorubicin + Trabectedin Reprab Study: PLD + Trabectedin Rechallenge (MITO36) Unknown status ITA 0
NCT04919629 Phase II Bevacizumab Bevacizumab + Pegcetacoplan + Pembrolizumab Pegcetacoplan + Pembrolizumab APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Recruiting USA 0
NCT04931342 Phase II Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 5
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Completed ESP 1
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05009082 Phase III Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Recruiting DEU 0
NCT05041257 Phase II Mirvetuximab Soravtansine Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 1
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05092360 Phase III Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 5
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05116189 Phase III Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | AUS 15
NCT05145569 Phase I Bintrafusp alfa + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer Not yet recruiting USA 0
NCT05156892 Phase I Itraconazole + Tamoxifen Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC) Recruiting AUS 0
NCT05183984 Phase II Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1) Recruiting FRA 1
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05198804 Phase Ib/II Niraparib + ZN-c3 A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Recruiting USA | FRA 0
NCT05199272 Phase Ib/II 23ME-00610 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies Active, not recruiting USA | CAN 0
NCT05231122 Phase II Bevacizumab + CDX-1140 + Pembrolizumab Bevacizumab + Pembrolizumab Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Recruiting USA 0
NCT05233982 Phase II Olaparib MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a) Recruiting ITA 0
NCT05257408 Phase III Nab-paclitaxel Nab-paclitaxel + Relacorilant Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 6
NCT05261490 Phase Ib/II Pegylated liposomal doxorubicin + TTI-622 Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer Terminated USA 0
NCT05277051 Phase I GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN | AUS 3
NCT05317078 Phase I AMG 794 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Active, not recruiting USA | AUS 1
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 16
NCT05335993 Phase II Niraparib + Oregovomab A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Active, not recruiting USA 0
NCT05403554 Phase I NI-1801 A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers Recruiting ITA | FRA 0
NCT05445778 Phase III Bevacizumab + Mirvetuximab Soravtansine Bevacizumab Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) Recruiting USA | ITA | GBR | ESP | CAN | BEL | AUS 4
NCT05453825 Phase II Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT05456685 Phase II Carboplatin + Mirvetuximab Soravtansine IMGN853 With Carboplatin in Second-line Treatment of FRalpha Expressing, Platinum-sensitive Epithelial Ovarian Cancer Active, not recruiting USA | GBR | ESP | CAN | BEL 1
NCT05467670 Phase II Doxorubicin + Evorpacept + Pembrolizumab Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer Recruiting USA 0
NCT05483933 Phase I Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Enrolling by invitation USA | GBR | ESP | CAN 0
NCT05527184 Phase I IMGN151 First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Recruiting USA 0
NCT05538091 Phase II Atezolizumab + Vismodegib Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Recruiting USA 0
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05672095 Phase Ib/II Niraparib Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Not yet recruiting USA 0
NCT05672459 Phase Ib/II IVS-3001 Cyclophosphamide + Fludarabine A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors Recruiting USA 0
NCT05691504 Phase I APG-1252 + Cobimetinib Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Recruiting USA 0
NCT05708924 Phase I FT538 FT538 + MGA271 MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Suspended USA 0
NCT05735080 Phase Ib/II INX-315 Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) Recruiting USA | AUS 0
NCT05739981 Phase II Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD) Recruiting USA 0
NCT05756907 Phase Ib/II Atezolizumab + SON-1010 SON-1010 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer Recruiting USA | AUS 0
NCT05794659 Phase II Carboplatin + Paclitaxel + Sargramostim Carboplatin + Paclitaxel + pUMVC3-hIGFBP-2 vaccine + Sargramostim Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone4) Not yet recruiting USA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05920798 Phase Ib/II FR alpha peptide vaccine + Pembrolizumab A Study of FRaDCs for Ovarian Cancer Recruiting USA 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05983276 Phase II Carboplatin + Decitabine + Paclitaxel + Selinexor Carboplatin + Decitabine + Paclitaxel Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer Recruiting USA 0
NCT05985655 Phase Ib/II GTAEXS617 Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) Recruiting GBR | BEL 0
NCT05990192 Phase II Niraparib SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO) Not yet recruiting GBR 0
NCT06028932 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients Recruiting USA 0
NCT06040970 Phase Ib/II Cisplatin + Sacituzumab govitecan-hziy Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Not yet recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06083844 Phase II Bevacizumab + Cyclophosphamide + Pembrolizumab Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy Recruiting USA 0
NCT06121401 FDA approved Bevacizumab + Olaparib First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE) Recruiting ITA 0
NCT06130254 Phase I Adagrasib + Olaparib Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting 0
NCT06305299 Phase I Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells Not yet recruiting USA 0
NCT06321484 Phase I CIML-NK cells + Nogapendekin alfa inbakicept Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Not yet recruiting USA 0
NCT06365853 Phase II Mirvetuximab Soravtansine A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Not yet recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 1
NCT06400472 Phase I LY4170156 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Recruiting USA 0